Plenary Session:
287. Closing Plenary: 21st Century Cures in Infectious Disease
Sunday, October 8, 2017: 9:15 AM-10:45 AM
Room: 06AB

Learning Objectives:

At the conclusion of this session, participants will be able to:

  • describe the major evidence for a protective or therapeutic role of antibodies in infectious diseases
  • discuss mechanisms by which antibodies inhibit major viral pathogens
  • summarize the concept of structure-based vaccine design using information on antibody epitopes
  • describe the role of treatment in elimination of HCV infection
  • compare the roles of antiviral medication in prevention and treatment to eliminate HCV infection
  • summarize the obstacles to elimination of HCV infection¬†in the USA

Target Audience: Academicians, Clinicians, Epidemiologists, Fellows, Healthcare workers, HIV clinicians, HIV specialists, Hospital administrators, Hospital epidemiologists, Infection preventionists, Infectious diseases pediatricians, Infectious diseases physicians, Investigators, Lab personnel, Medical students and residents, Members-in-training, Microbiologists, Nurses, Pharmacists, Public health practitioners, Researchers, Scientists, Vaccinologists

Tracks: Trainee, Pediatric ID, Investigative ID, HIV-STD-TB, Global ID, Epidemiology and Infection Control, Adult ID

Moderators:  Andrew Pavia, MD, FIDSA, FSHEA, FPIDS, University of Utah School of Medicine and Rajesh Gandhi, MD, FIDSA, Massachusetts General Hospital

CME Credits: Maximum of 1.50 hours of AMA PRA Category 1 Credit™

ACPE Credits: ACPE 1.5 knowledge-based contact hours of pharmacy CE

ACPE Number: 0221-9999-17-384-L01-P


A. Pavia, None

R. Gandhi, Gilead: Educational grant to MGH , Educational grant
Merck: Educational grant to MGH , Educational grant
Viiv: Educational grant to MGH , Educational grant
Theratechnologies: Scientific Advisor , Consulting fee
EMD Serono: Consultant , Consulting fee

See more of: Plenary Session
<< Previous Session | Next Session >>

Findings in the abstracts are embargoed until 12:01 a.m. PDT, Wednesday Oct. 4th with the exception of research findings presented at the IDWeek press conferences.